Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

INTRODUCTION: Septic shock is the subgroup of patients with sepsis, which presents as vasopressor dependence, an elevated blood lactate concentration and is associated with a mortality of at least 30%. Expression of the triggering receptor expressed on myeloid cells 1 (TREM-1) pathway, measured usin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open
Auteurs principaux: Francois, Bruno, Lambden, Simon, Gibot, Sebastien, Derive, Marc, Olivier, Aurelie, Cuvier, Valerie, Witte, Stephan, Grouin, Jean-Marie, Garaud, Jean Jacques, Salcedo-Magguilli, Margarita, Levy, Mitchell, Laterre, Pierre-François
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2021
Sujets:
Intensive Care
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264912/
https://ncbi.nlm.nih.gov/pubmed/34233965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-042921
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires